Courage for Cures Adds U-M Pediatric Brain Tumor Initiative to Brave Knight Beneficiaries

Dr. Carl Koschmann, a pediatric oncologist and researcher at the University of Michigan C.S. Mott Children's Hospital in Ann Arbor.

In partnership with The ChadTough Foundation’s extraordinary efforts to fund the development of a world-class pediatric brain tumor research and treatment center in our home state of Michigan, Courage for Cures will add the Michigan Medicine Pediatric Brain Tumor Initiative as one of its beneficiaries of our upcoming 7th Brave Knight benefit.

Announced earlier this year, The Michigan Medicine Pediatric Brain Tumor Initiative is working to raise $50 million for the research and development of new therapies for childhood brain cancer. Just this month, University of Michigan researchers announced that by analyzing the donation of Chad Carr’s tumor cells, they discovered a genetic mutation called PTEN that drove the growth of his cancer. The Detroit Free Press reported that, “The revelation carries hope for an effective treatment for some of the roughly 300 children who get the same terminal diagnosis each year in the U.S.”


Since our first Brave Knight event in 2011, Courage for Cures has funded $330,000 in research grants around the world approved by The DIPG Collaborative’s Medical Advisory Council and $150,000 in research and patient programs at St. Jude Children’s Research Hospital.


Julian was treated at both St. Jude in Memphis and U-M Mott Children’s Hospital closer to home during his 7-month battle with an aggressive brain stem glioma.


The 7th Brave Knight benefit will be held on Friday, Nov. 10 at Pine Lake Country Club. Tickets are now on sale.